Answers are grounded in this paper and cite their sources.
Flibanserin was approved by the US FDA in 2015 and by Health Canada in 2018 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Flibanserin was subsequently approved by Health Canada for treating acquired, generalized HSDD in naturally postmenopausal women who are 60 years of age or younger. Yet, data regarding flibanserin’s efficacy and safety continue to be misunderstood. Our recent post-hoc analyses of the effects of flibanserin further characterized changes in aspects of sexual function beyond sexual desire. Spielmans’ commentary on our publication attempts to characterize flibanserin’s efficacy as being “unimpressive” and “likely not clinically meaningful”. Spielmans opines that the reported effect sizes in our analyses were too small, that our discussion comparing effect sizes and NNT estimates for flibanserin to those of antidepressants is irrelevant, that the PGI-I data have no clinical relevance, and that the Female Sexual Function Index (FSFI) has questionable validity as a measure of sexual function in women with HSDD.
No takes yet. Share an insight, caveat, or question.
Simon et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: